Labcorp (NYSE:LH) EVP Sells $156,130.68 in Stock

Labcorp Holdings Inc. (NYSE:LH) EVP Der Vaart Sandra Van sold 548 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the completion of the sale, the executive vice president directly owned 2,579 shares in the company, valued at $734,782.89. This trade represents a 17.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Labcorp Stock Down 1.8%

Shares of NYSE LH opened at $275.80 on Friday. The company has a market cap of $22.73 billion, a price-to-earnings ratio of 26.37, a PEG ratio of 1.92 and a beta of 1.01. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. Labcorp Holdings Inc. has a 12 month low of $209.38 and a 12 month high of $293.72. The stock has a 50-day moving average price of $270.68 and a two-hundred day moving average price of $270.30.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.12. The company had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, analysts forecast that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, February 27th. Labcorp’s payout ratio is presently 27.53%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their price objective on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Finally, Piper Sandler upped their price target on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Labcorp currently has a consensus rating of “Moderate Buy” and a consensus target price of $304.82.

Institutional Trading of Labcorp

Institutional investors have recently added to or reduced their stakes in the stock. REAP Financial Group LLC increased its position in Labcorp by 20.4% during the 4th quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 37 shares during the period. SP Asset Management LLC boosted its stake in shares of Labcorp by 0.3% in the 2nd quarter. SP Asset Management LLC now owns 14,177 shares of the medical research company’s stock valued at $3,722,000 after purchasing an additional 38 shares during the last quarter. HBK Sorce Advisory LLC increased its position in shares of Labcorp by 4.3% during the third quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company’s stock worth $254,000 after buying an additional 38 shares during the period. Pure Financial Advisors LLC raised its stake in Labcorp by 3.9% during the third quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company’s stock worth $292,000 after buying an additional 38 shares during the last quarter. Finally, Zions Bancorporation National Association UT raised its stake in Labcorp by 21.9% during the second quarter. Zions Bancorporation National Association UT now owns 223 shares of the medical research company’s stock worth $59,000 after buying an additional 40 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.